Veracyte Inc VCYT:NASDAQ

Last Price$33.79NASDAQ Closing Price as of 4:00PM ET 8/14/20

Today's Change-1.03(2.96%)
Bid (Size)$27.05 (2)
Ask (Size)$36.00 (1)
Day Low / High$33.73 - 35.03
Volume361.4 K

View Biotechnology IndustryPeer Comparison as of 08/14/2020


Veracyte Inc ( NASDAQ )

Price: $33.79
Change: -1.03 (2.96%)
Volume: 361.4 K
4:00PM ET 8/14/2020

Xencor Inc ( NASDAQ )

Price: $32.90
Change: -0.47 (1.41%)
Volume: 169.9 K
4:00PM ET 8/14/2020

Ligand Pharmaceuticals Inc ( NASDAQ )

Price: $113.25
Change: +0.05 (0.04%)
Volume: 146.1 K
4:00PM ET 8/14/2020

Kodiak Sciences Inc ( NASDAQ )

Price: $47.88
Change: -0.32 (0.66%)
Volume: 104.6 K
4:00PM ET 8/14/2020

Seres Therapeutics Inc ( NASDAQ )

Price: $27.26
Change: -1.32 (4.62%)
Volume: 3.2 M
4:00PM ET 8/14/2020

Read more news Recent News

Veracyte (VCYT) sees Significant Insider Selling Continuing
10:21PM ET 8/05/2020 MT Newswires

There was a notable insider sale of Veracyte shares today, as revealed in a filing with the SEC as -- Evan Jones, Director -- sold 40,000 shares in the...

Veracyte Says Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
3:39PM ET 8/05/2020 MT Newswires

Veracyte (VCYT) said Wednesday that new data showed its Percepta classifier significantly reduces invasive procedures in lung cancer diagnosis by...

Insider Trends: Veracyte Insider Extends 90-Day Selling Trend
8:01PM ET 8/04/2020 MT Newswires

Evan Jones, Director, on Jul 31, 2020, sold 40,000 shares in Veracyte (VCYT) for $1,416,423. Jones, subsequent to the transactions designated in the SEC...

Veracyte Kicks off Underwritten Offering of 6 Million Shares
2:06PM ET 8/04/2020 MT Newswires

Veracyte (VCYT) said late Monday it has begun an offering of 6 million shares. It also plans to offer underwriters a 30-day option to purchase up to...

Company Profile

Business DescriptionVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
Address6000 Shoreline Court
South San Francisco, California 94080
Number of Employees270
Recent SEC Filing08/12/20204
Chairman & Chief Executive OfficerBonnie H. Anderson
Chief Operating & Financial OfficerKeith Kennedy
Chief Scientific & Medical OfficerGiulia C. Kennedy
Secretary, Executive VP & General CounselJames H. Erlinger

Company Highlights

Price Open$34.92
Previous Close$34.82
52 Week Range$13.90 - 36.42
Market Capitalization$1.7 B
Shares Outstanding50.6 M
SectorHealth Technology
Next Earnings Announcement10/27/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.62
Beta vs. S&P 500N/A
Revenue$92.0 M
Net Profit Margin-27.49%
Return on Equity-13.35%

Analyst Ratings as of 05/28/2020

Consensus RecommendationConsensus Icon
Powered by Factset